Announcements Trials

Browse Landscape

Clinical Trials

1 trials

Recent Start date Enrollment

Gastroenteropancreatic Neuroendocrine Tumor G3 × anlotinib × Endocrine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Gastrointestinal 1 Endocrine 1

Conditions

Pheochromocytoma 4 Paraganglioma 3 Paraganglioma, Extra-Adrenal 1 Neuroendocrine Tumors 1 Neoplasm Metastasis 1 Gastroenteropancreatic Neuroendocrine Tumor G3 1 Digestive System Neoplasms 1 Differentiated Thyroid Cancer 1 Advanced Thyroid Cancer Patients Who Received Target Therapy 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03457844 2018-09-11

A Study of Anlotinib in Patients With Gastroenteropancreatic Neuroendocrine Tumor G3

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Unknown

EndocrineGastrointestinalNET

Gastroenteropancreatic Neuroendocrine Tumor G3

Data powered by HemOnc (CC BY 4.0) Colophon ⚡